On or around 12/04/2018 (Stipulation and order of dismissal (voluntary dismissal))
Filing Date: January 02, 2018
According to the Complaint, Ekso designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa.
The law firm press release alleges that Defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) there was a material weakness in Ekso’s internal control over financial reporting and Ekso’s disclosure controls and procedures were not effective; and (2) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
On March 20, 2018, this case was transferred to the Northern District of California. On June 15, the Court appointed Lead Plaintiff and Counsel. On November 29, this case was voluntarily dismissed.
Company & Securities Information
Defendant: Ekso Bionics Holdings, Inc.
Industry: Medical Equipment & Supplies
Headquarters: United States
Ticker Symbol: EKSO
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Rimon Bekhet, et al. v. Ekso Bionics Holdings, Inc., et al.